EGFR and non-small cell lung carcinoma: The prognosis of patients with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) sensitizing mutations has significantly improved with EGFR-tyrosine kinase inhibitor (TKI) therapy.1